Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer

[1]  Seema A. Khan,et al.  RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase , 2014, Breast Cancer Research and Treatment.

[2]  C. Denkert,et al.  RANK expression as a prognostic and predictive marker in breast cancer , 2014, Breast Cancer Research and Treatment.

[3]  Y. Matsuno,et al.  Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer , 2014, Breast Cancer Research and Treatment.

[4]  Wassim Raffoul,et al.  Progesterone/RANKL Is a Major Regulatory Axis in the Human Breast , 2013, Science Translational Medicine.

[5]  M. Dowsett,et al.  Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance , 2013, Clinical Cancer Research.

[6]  M. Dowsett,et al.  Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer , 2013, Breast Cancer Research and Treatment.

[7]  M. Mason,et al.  Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. , 2013, Anticancer research.

[8]  Mark T. W. Ebbert,et al.  PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers , 2012, BMC Medical Genomics.

[9]  M. Dowsett,et al.  Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer , 2012, Breast Cancer Research.

[10]  K. Janes,et al.  Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression , 2011, Proceedings of the National Academy of Sciences.

[11]  D. Branstetter,et al.  RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis , 2010, Nature.

[12]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Perou,et al.  Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Mitsutaka Kadota,et al.  Delineating Genetic Alterations for Tumor Progression in the MCF10A Series of Breast Cancer Cell Lines , 2010, PloS one.

[15]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Dowsett,et al.  A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer , 2009, Breast Cancer Research and Treatment.

[17]  P. Buchan,et al.  Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone , 2009, Breast Cancer Research and Treatment.

[18]  M. Sherman,et al.  Recent trends in breast cancer among younger women in the United States. , 2008, Journal of the National Cancer Institute.

[19]  Jingqin Luo,et al.  Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics , 2008, Journal of the National Cancer Institute.

[20]  Jennifer L. Osborn,et al.  Direct multiplexed measurement of gene expression with color-coded probe pairs , 2008, Nature Biotechnology.

[21]  Mitch Dowsett,et al.  Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.

[22]  T. Curry,et al.  Luteinizing hormone-induced RUNX1 regulates the expression of genes in granulosa cells of rat periovulatory follicles. , 2006, Molecular endocrinology.

[23]  M. Dowsett,et al.  Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[25]  R. Clarke,et al.  Steroid Receptors and Cell Cycle in Normal Mammary Epithelium , 2004, Journal of Mammary Gland Biology and Neoplasia.

[26]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[27]  A. Luini,et al.  Timing of breast cancer surgery in relation to the menstrual cycle: an update of developments. , 2001, Critical reviews in oncology/hematology.

[28]  J. Klijn,et al.  Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. , 2000, Journal of the National Cancer Institute.